SREBF1 and fatty liver disease: De novo lipogenesis is largely involved in inducing hepatic steatosis as demonstrated in a previous report showing that SREBP-1 ablation protected ob/ob mice from hepatic steatosis irrespective of adiposity and systemic glucose metabolism [26].